Abstract: Pancreatic and duodenal homeobox (Pdx1) is a homeobox transcription factor required for the embryonic development of the pancreas. Pdx1 expression has been earlier identified in pancreatic ductal adenocarcinomas and endocrine neoplasms. This study characterizes Pdx1 protein expression in pancreatic precursor lesions and neoplasms, including pancreatic intraepithelial neoplasia (PanIN, n=32), intraductal papillary mucinous neoplasm (IPMN, n=88), mucinous cystic neoplasm (MCN, n=3), acinar cell carcinoma (ACC, n=8), pancreatic endocrine neoplasm (PEN, n=44), pancreatoblastoma (PB, n=1), solid pseudopapillary neoplasm (n=8), invasive ductal adenocarcinoma (n=67), and nondysplastic ductal epithelium. A mouse monoclonal antibody for Pdx1 was used to examine archived surgical pathology cases and tissue microarrays containing >655 tissue cores from more than 250 pancreatic specimens. Immunohistochemical labeling for Pdx1 was performed using standard methods and scored for percentage and intensity of nuclear labeling. Among non-neoplastic pancreatic tissues, Pdx1 nuclear protein was expressed in islet cells, cells of the centroacinar cell compartment, and non-neoplastic ductal epithelium. No expression of Pdx1 was seen in non-neoplastic acinar cells. Among pancreatic neoplasms, Pdx1 consistently labeled >50% of the tumor cells in 87.5% of ACC cases and 38.6% of PEN cases. Pdx1 expression was variable in invasive ductal adenocarcinoma and precursor lesions of ductal adenocarcinomas (PanIN, IPMN, and  MCN) . A single case of PB was examined and it showed Pdx1 in the acinar component, but no expression in squamoid nests. Solid pseudopapillary neoplasms did not express Pdx1. This study shows Pdx1 expression in precursor lesions of ductal adenocarcinomas, PEN, ACC, and a case of PB. In the immunohistochemical evaluation of neoplasms of the pancreas, Pdx1 expression is not a finding specific to PENs and ductal adenocarcinomas, but also occurs in precursor lesions (PanIN, IPMN, MCN) and other neoplasms of the pancreas.
P
ancreatic and duodenal homeobox 1 (Pdx1) is a critical transcription factor in the embryologic development of the pancreas. 1 Pdx1 is important for both the embryologic development of the pancreas and the maintenance of mature pancreatic islets. Homozygous deletion of Pdx1 in the mouse results in pancreatic agenesis 2 ; similarly, a patient with pancreatic agenesis was studied and found to have single nucleotide deletion in the Pdx1 coding region. 3 The mechanisms and patterns of pancreatic Pdx1 expression in injury and carcinogenesis have been elucidated over the last decade. Initially, much of the work focused on the induction of Pdx1 expression in animal models of injury. One of the initial studies observed induction of Pdx1 in a rat model of pancreatectomyinduced pancreas regeneration. 4 This study showed a positive correlation between ductal proliferation after pancreatectomy and Pdx1 protein levels. In addition to the studies of the regulation of Pdx1 expression, the Pdx1 promoter has been used as a tool for pancreatic specific expression in transgenic mice. [5] [6] [7] [8] On account of Pdx1's key role in the embryologic development of the pancreas and its induction in injury and regeneration, the expression of Pdx1 has been examined in pancreatic cancer cell lines and human tumors. [9] [10] [11] Studies of human pancreatic carcinomas have found Pdx1 to be expressed in approximately 40% of pancreatic ductal carcinomas with minimal expression in the pancreatic exocrine tissue adjacent to tumor. Pdx1 expression in pancreatic carcinomas has been shown to positively correlate with lymph node metastasis and increased mortality. In these earlier studies, pancreatic cancer metastases were found to retain Pdx1 protein expression; indeed, liver metastases had higher expression compared with the primary tumors. Taken together, the earlier studies of Pdx1 expression in pancreatic cancers suggest that Pdx1 expression in pancreatic ductal carcinomas is a poor prognostic factor. There have been several studies that examined Pdx1 expression in nonductal carcinomas, including pancreatic endocrine neoplasms (PENs), 12, 13 and solid pseudopapillary neoplasms.
14 This study is an investigation of Pdx1 expression in precursor lesions of pancreatic ductal adenocarcinomas and pancreatic neoplasms that have not been earlier characterized.
MATERIALS AND METHODS
This study was carried out at the Johns Hopkins University and approved by the Johns Hopkins University Institutional Review Board.
Tissue Specimens
As earlier described, tissue microarrays were constructed from surgical pathology samples in the archives of the Department of Pathology at the Johns Hopkins Hospital and Memorial Sloan-Kettering Cancer Center. 15 The archived samples consisted of formalin-fixed paraffinembedded tissue blocks. Representative paraffin tissue cores were punched by a manual tissue punch/arrayer (Beecher Instruments, Silver Spring, MD). Four cores with a 1.4 mm diameter were extracted from each case and were transferred into recipient tissue microarray blocks. Cases with loss of either lesion or matched normal cores were excluded from this study. After excluding these cases, we evaluated Pdx1 nuclear labeling in 12 tissue microarrays containing >655 tissue cores from more than 250 specimens. These tissue specimens included non-neoplastic normal tissue controls and the following lesions: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), acinar cell carcinomas (ACC), well-differentiated PEN, solid pseudopapillary neoplasms (SPN), invasive ductal adenocarcinoma, and nondysplastic ductal epithelium. A single pancreatoblastoma (PB) case was evaluated from a standard section of a paraffin block. In the case of IPMN, subtype analysis based on intestinal, pancreatobiliary, or gastric type was not carried out.
A subset of the tissue microarray cases were from 67 patients with pancreatic ductal adenocarcinomas who had pancreatic surgery (Whipple procedure, distal pancreatectomy, or total pancreatectomy) at the Johns Hopkins Hospital and had survival information established earlier. 16 Of the 67 patients, 37 were men and 30 were women. They had a mean age of 69.0 years at the time of surgery (range, 39 to 90 y).
Several non-neoplastic extrapancreatic tissues with no pathologic changes were also examined for Pdx1 nuclear labeling including 15 stomach, 8 duodenum, 10 small intestines (jejunum), 4 large intestines, 3 gall bladder, 25 liver, 11 prostate, 23 kidney, 11 ovary, 4 skin, 11 spleen, 7 thyroid, 8 lung, 10 breast, 18 brain (cerebellum), 10 tonsils, and 3 placenta.
Immunohistochemistry
Pdx1 mouse monoclonal antibody that recognizes the C-terminus of Pdx1 (amino acids 91 to 283) (MAB2419, clone 267712; R&D Systems, Minneapolis, MN) was used for immunohistochemistry. In brief, formalin-fixed paraffin-embedded tissue sections were stained on a Bond-Leica autostainer (Leica Microsystems, Bannockburn, IL). All tissue sections were baked for 20 minutes at 651C before loading on the autostainer. Heat induced epitope retrieval was performed by high pH (8.0) buffer. This was followed by a 15-minute incubation at room temperature with the primary antibody at 1:100 and 1:50 dilutions for TMA and standard paraffin tissue sections, respectively. The reaction was developed with the biotin-free Bond Polymer Refine Detection system (Leica Microsystems, Bannockburn, IL). A secondary antimouse antibody conjugated to 3,3 0 -diaminobenzidine label was used as a chromogenic reporter molecule. Negative controls included nonpancreatic tissue and normal saline substitution for primary antibody.
Scoring
Immunohistochemical labeling for Pdx1 on TMA were scored by 2 pathologists (J.Y.P. and S.M.H.). Each tissue type was scored for the percentage of positive nuclear labeling (0=0%, 1=1% to 25%, 2=26% to 50%, 3=51% to 75%, 4=76% to 100%). In addition, a composite score was created by multiplying the percentage score by an intensity of nuclear labeling (0, 1+, 2+). The controls for scoring were the nuclei of Pdx1-labeled islet cells (eg, islet cells have a percentage score of "4" multiplied by an intensity score of "2" for the maximum composite score of "8").
Statistical Analysis
Analysis of variance and Duncan test was carried out for comparison of the composite immunohistochemistry scores. Overall patients' survival was defined as the time from surgical resection of pancreatic ductal adenocarcinomas to the death of the patients or the last followup of the patients. Survival rates were calculated using the Kaplan-Meier method and statistical significance was evaluated using the log-rank test. P values <0.05 were considered significant.
RESULTS
The tissue from TMAs available for evaluation included 250 unique tumors and precursor lesions including: 32 PanIN, 88 IPMN, 3 MCN, 8 ACC, 44 PEN, 8 SPN, and 67 invasive ductal adenocarcinomas (Table 1) . There were an additional 73 TMA cases of nondysplastic ductal epithelia from pancreatic cancer resection cases. A single PB case was evaluated by immunohistochemistry separate from the TMA cases.
Pdx1 nuclear labeling by immunohistochemistry was consistently present in the non-neoplastic islet cells and cells of the centroacinar cell compartment (Figs. 1A, B) . No acinar cell labeling was identified (Fig. 1C) . Outside the centroacinar cell compartment, weak and variable Pdx1 nuclear labeling was identified in both intralobular and interlobular ducts. Nondysplastic duct epithelia in 56% of cases had Pdx1 nuclear labeling in >50% of the cells examined (Table 1) .
In nonpancreatic tissues, consistent labeling of epithelium of the duodenum was observed ( Fig. 2A) . In addition to labeling the nuclei of cells from the base of the crypts to the villous tips, focal Pdx1 nuclear labeling was seen in Brunner's glands. In the limited number of gastric mucosal specimens examined, no Pdx1 labeling was seen in the parietal, chief, neuroendocrine or mucous necks cells (Figs. 2B, C) ; however, a focus of intestinal metaplasia in oxyntic mucosa had uniform Pdx1 labeling (Fig. 2B) . Weak Pdx1 nuclear labeling was seen in the basal layer of the skin. No Pdx1 labeling was seen in colonic mucosa (Fig. 2D) . In addition, no Pdx1 labeling was seen in gallbladder, liver, prostate, kidney, ovary, spleen, thyroid, lung, breast, cerebellum, tonsils, and placenta (data not shown).
Frequent and sometimes strong labeling of the precursor lesions of pancreatic ductal adenocarcinoma was observed. In PanIN lesions, 40.6% of cases had Pdx1 nuclear labeling in >50% of the cells examined. For IPMNs, 35.2% of cases had Pdx1 nuclear labeling in >50% of the cells examined (Fig. 3A) . There was no significance difference according to degree of dysplasia of the IPMN. Similarly, for MCNs, 2 of the 3 cases had Pdx1 nuclear labeling in >50% of the cells. Invasive pancreatic ductal adenocarcinomas were more variable in their nuclear Pdx1 labeling; the majority had no Pdx1 labeling. However, there was a subset of carcinomas with strong nuclear labeling in the majority of cells examined (Fig. 3B) . Nine of 67 cases (13.4% of all ductal adenocarcinomas) had >50% of cells labeled. The median survival time for the patients with Pdx1 higher (score Z4) and lower (score <4) expression was 17.8 and 15.1 months, respectively. However, this was not a significant survival difference (P=0.95, Table 2 , Fig. 4 ).
The nonductal neoplasms had varying levels of Pdx1 expression as measured by Pdx1 nuclear labeling. Well-differentiated PENs had strong Pdx1 expression in a subset. No Pdx1 labeling was seen in 47.7% of cases, but 38.6% of cases (17 of 44) had consistent nuclear Pdx1 labeling in >50% of the tumor cells (Table 1; Fig. 3C ). For ACCs, 87.5% cases (6 of 8) had nuclear labeling in >50% of the tumors cells; furthermore, ACCs had the highest composite score, which was significantly higher than all other ductal or nonductal neoplasm groups analyzed (mean composite score, 4.58; P<0.0001, analysis of variance; P=0.05, post hoc Duncan test). All the cases of ACC had strong Pdx1 expression in >25% of cells; most cases had a strong and diffuse pattern of expression (Fig. 3D) . Interestingly, the single PB case examined exhibited strong nuclear Pdx1 labeling only in its acinar component (Fig. 3E) . The squamoid nests in the PB did not label with Pdx1. All SPNs were negative for nuclear and cytoplasmic labeling with Pdx1 (Fig. 3F) .
DISCUSSION
We report that Pdx1 protein expression in human pancreatic ductal epithelium is not lost after embryologic development, and indeed expression occurs in nonneoplastic cells of the centroacinar cell compartment in addition to islet cells. Furthermore, Pdx1 expression occurs in multiple types of pancreatic neoplasms that express different lines of epithelial differentiation: ductal adenocarcinomas, endocrine neoplasms, ACCs, and PBs. The pattern of Pdx1 expression in precursor lesions and neoplasms of the pancreas suggests that Pdx1 may have a wider role in pancreatic tumorigenesis. In practical terms, detection of Pdx1 expression in a pancreatic neoplasm is not specific for ductal adenocarcinomas or endocrine neoplasms.
Regarding the correlation of Pdx1 expression with survival of patients with pancreatic ductal adenocarcinomas, this study showed a lack of statistically significant difference in median survival based on Pdx1 expression. In an earlier study of 35 patients with pancreatic ductal adenocarcinomas, the expression of Pdx1 was correlated with a worse survival compared with cases without Pdx1 expression, 14.0 versus 21.4 months, respectively. 10 It is important to note that there are significant experimental differences in the antibody and immunohistochemical assay method used in this study and earlier study. Although this study did not reach statistically significant difference in survival, Pdx1 expression had a trend toward worse survival. A limitation of this study was the examination of a small percentage of the tumor volume limited to a tissue microarray core. Further studies that evaluate Pdx1 expression based on more extensive sampling of the tumor may be informative in determining the relationship of Pdx1 expression with survival in pancreatic ductal adenocarcinomas.
This study showed that Pdx1 was strongly expressed (>50% of nuclei) in 38.6% of well-differentiated endocrine neoplasms. This is similar to the findings of an earlier study of Pdx1 expression in PENs. 12 This earlier study not only examined Pdx1 in PENs, but also compared the expression FIGURE 3. Pdx1 expression in precursor lesions and neoplasms of the pancreas. Intraductal papillary mucinous neoplasms had frequent nuclear labeling (A). Ductal adenocarcinomas had variable nuclear labeling, but intensely labeled in some cases (B). Welldifferentiated endocrine neoplasms of the pancreas had frequent strong nuclear labeling (C). Acinar cell carcinomas had uniform intense labeling (D). Pancreatoblastomas had strong nuclear labeling, but only in the acinar component; the squamoid nests (*) were negative for pdx1 labeling (E). No Pdx1 labeling was seen in solid pseudopapillary neoplasms (F). pattern in gastrointestinal carcinoid and pulmonary carcinoid tumors. These investigators found that 28.2% (11 of 39) of PENs expressed Pdx1. In addition to expression in endocrine neoplasms primary to the pancreas, Pdx1 was found to be expressed in well-differentiated neuroendocrine neoplasms of the stomach and duodenum. Indeed, these investigators showed that positive Pdx1 immunohistochemistry may have diagnostic use in determining that the site of origin of metastatic well-differentiated neuroendocrine neoplasms is the pancreas or foregut. The focus of this study was not to examine Pdx1 expression in nonpancreatic tissue; however, the pattern of Pdx1 seen in the duodenum and stomach in this study confirms earlier reports. Pdx1 expression was not seen in the oxyntic or antral mucosa, but was identified in intestinal metaplasia. Earlier studies have identified no expression of Pdx1 in normal gastric fundus, but variable levels of expression in gastric antrum. [17] [18] [19] The lack of antral expression in this study may reflect sampling as the earlier studies were more extensive in their characterization of Pdx1 expression in the stomach. The finding of Pdx1 expression in intestinal metaplasia and gastric adenocarcinomas has been identified earlier. 17, 18 In addition, Pdx1 has been earlier identified in Menetrier's Disease 19 and various serrated lesions of the colon (hyperplastic polyps, sessile serrated adenomas, and traditional serrated adenomas). 20 This study identified that Pdx1 was strongly expressed in precursor lesions of pancreatic adenocarcinomas (PanIN, IPMN, and MCN) ; however, there is no correlation between the degree of dysplasia and the intensity of labeling. Furthermore, non-neoplastic ductules not directly associated with tumors frequently labeled with Pdx1. This study did not specifically examine the differences in Pdx1 expression based on the location of non-neoplastic ductules. On the basis of earlier published experimental studies in animals, Pdx1 may be re-expressed in pancreatic ducts that are exposed to pancreatitis. 4 Thus, this finding of extensive Pdx1 expression in the neoplastic and non-neoplastic ducts may be the result of chronic damage or obstruction. The nonneoplastic pancreas ducts examined in this study were uninvolved by tumor, but were from pancreas resected for tumor and may not be representative of truly normal pancreas. Future examination of human pancreas that has no association with tumor or chronic damage will be informative to the state of Pdx1 expression in normal pancreas.
In summary, this study confirms previous reports of Pdx1 expression in pancreatic ductal carcinoma and endocrine neoplasms. The novel findings in this study are that Pdx1 is also expressed in non-neoplastic ducts, precursors of ductal carcinoma (PanIN, IPMN, MCN) and non-ductal neoplasms (ACC, PB).
